Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 9-11, 2024. Company management will also be participating in one-on-one meetings during the conference.

The on-demand presentation will be available for viewing beginning September 9 at 7:00 a.m. ET. An archived replay of the presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.

H.C. Wainwright 26th Annual Global Investment Conference – September 9-11, 2024

Format: Azitra Inc., Corporate Presentation

Date/Time: Available on-demand Monday, September 9, 2024 at 7:00 AM ET

Participant: Travis Whitfill, Chief Operating Officer

Location: Lotte New York Palace Hotel, New York City, NY

Webcast Link: Here

About Azitra, Inc.

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described and incorporated by reference more fully in the section titled “Risk Factors” in our Form 10-Q filed with the SEC on August 12, 2024. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240906297209/en/

Investor Relations Contact: Norman Staskey Chief Financial Officer [e-mail]

Hayden IR James Carbonara [phone] [e-mail]